Axela, Xceed Molecular Corp. deal

Axela acquired Xceed Molecular for an undisclosed sum. Axela gains Xceed's Ziplex System for gene-expression analysis, Breast Cancer Prognostic Assay and Colon Cancer Xpress Chip. The company expects to submit a 510(k) to FDA in 2H11 for its Breast Cancer Prognostic Assay, a gene-expression signature to predict the risk of recurrence for breast cancer patients. Xceed's Colon Cancer Xpress Chip, which is used to compare gene expression profiles in human colorectal carcinomas and normal colorectal tissue, is already available for research only. The companies said the acquisition blends Axela's research focus with Xceed's diagnostic programs. ...